Search Results - "BERTSCH, Uta"

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project by D'Agostino, Mattia, Cairns, David A, Lahuerta, Juan José, Wester, Ruth, Bertsch, Uta, Waage, Anders, Zamagni, Elena, Mateos, María-Victoria, Dall'Olio, Daniele, van de Donk, Niels W C J, Jackson, Graham, Rocchi, Serena, Salwender, Hans, Bladé Creixenti, Joan, van der Holt, Bronno, Castellani, Gastone, Bonello, Francesca, Capra, Andrea, Mai, Elias K, Dürig, Jan, Gay, Francesca, Zweegman, Sonja, Cavo, Michele, Kaiser, Martin F, Goldschmidt, Hartmut, Hernández Rivas, Jesús María, Larocca, Alessandra, Cook, Gordon, San-Miguel, Jesús F, Boccadoro, Mario, Sonneveld, Pieter

“…Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the…”
Get full text

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients by Weinhold, Niels, Salwender, Hans J, Cairns, David A, Raab, Marc S, Waldron, George, Blau, Igor W, Bertsch, Uta, Hielscher, Thomas, Morgan, Gareth J, Jauch, Anna, Davies, Faith E, Hänel, Mathias, Cook, Gordon, Scheid, Christoph, Houlston, Richard, Goldschmidt, Hartmut, Jackson, Graham, Kaiser, Martin F

Get full text

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial by SONNEVELD, Pieter, SCHMIDT-WOLF, Ingo G. H, WEISEL, Katja C, WITTEBOL, Shulamiet, BOS, Gerard M. J, STEVENS-KROEF, Marian, SCHEID, Christof, PFREUNDSCHUH, Michael, HOSE, Dirk, JAUCH, Anna, DER VELDE, Helgi Van, RAYMAKERS, Reinier, DER HOLT, Bronno Van, SCHAAFSMA, Martijn R, KERSTEN, Marie-Jose, MARWIJK-KOOY, Marinus Van, DUEHRSEN, Ulrich, LINDEMANN, Walter, WIJERMANS, Pierre W, LOKHORST, Henk M, GOLDSCHMIDT, Hartmut M, EL JARARI, Laila, BERTSCH, Uta, SALWENDER, Hans, ZWEEGMAN, Sonja, VELLENGA, Edo, BROYL, Annemiek, BLAU, Igor W

“…We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). In all, 827 eligible patients…”
Get full text

Selective elimination of immunosuppressive T cells in patients with multiple myeloma by Awwad, Mohamed H. S., Mahmoud, Abdelrahman, Bruns, Heiko, Echchannaoui, Hakim, Kriegsmann, Katharina, Lutz, Raphael, Raab, Marc S., Bertsch, Uta, Munder, Markus, Jauch, Anna, Weisel, Katja, Maier, Bettina, Weinhold, Niels, Salwender, Hans Jürgen, Eckstein, Volker, Hänel, Mathias, Fenk, Roland, Dürig, Jan, Brors, Benedikt, Benner, Axel, Müller-Tidow, Carsten, Goldschmidt, Hartmut, Hundemer, Michael

“…Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed…”
Get full text

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial by Goldschmidt, Hartmut, Mai, Elias K., Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Merz, Maximilian, Munder, Markus, Lindemann, Hans-Walter, Hügle-Dörr, Barbara, Tichy, Diana, Giesen, Nicola, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Rabold, Bernhard, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Salwender, Hans J.

“…The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR)…”
Get full text

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients by Broyl, Annemiek, Hose, Dirk, Lokhorst, Henk, de Knegt, Yvonne, Peeters, Justine, Jauch, Anna, Bertsch, Uta, Buijs, Arjan, Stevens-Kroef, Marian, Beverloo, H. Berna, Vellenga, Edo, Zweegman, Sonja, Kersten, Marie-Josée, van der Holt, Bronno, el Jarari, Laila, Mulligan, George, Goldschmidt, Hartmut, van Duin, Mark, Sonneveld, Pieter

“…To identify molecularly defined subgroups in multiple myeloma, gene expression profiling was performed on purified CD138+ plasma cells of 320 newly diagnosed…”
Get full text

The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs) by Sachpekidis, Christos, Merz, Maximilian, Raab, Marc-Steffen, Bertsch, Uta, Weru, Vivienn, Kopp-Schneider, Annette, Jauch, Anna, Goldschmidt, Hartmut, Dimitrakopoulou-Strauss, Antonia

“…Purpose [ 18 F]FDG PET/CT is the elective imaging modality for treatment monitoring in multiple myeloma (MM). However, MM is a heterogeneous disease from an…”
Get full text

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial by Broyl, Annemiek, Dr, Corthals, Sophie L, MSc, Jongen, Joost LM, MD, van der Holt, Bronno, PhD, Kuiper, Rowan, BSc, de Knegt, Yvonne, BSc, van Duin, Mark, PhD, el Jarari, Laila, MSc, Bertsch, Uta, MD, Lokhorst, Henk M, Prof, Durie, Brian G, MD, Goldschmidt, Hartmut, Prof, Sonneveld, Pieter, Prof

“…Summary Background Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of…”
Get full text

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age by Mai, Elias K., Miah, Kaya, Bertsch, Uta, Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Benner, Axel, Salwender, Hans J., Goldschmidt, Hartmut

“…Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem…”
Get full text

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial by Salwender, Hans, Elmaagacli, Ahmet, Merz, Maximilian, Miah, Kaya, Benner, Axel, Haenel, Mathias, Jehn, Christian, Mai, Elias K., Bertsch, Uta, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Raab, Marc S., Luntz, Steffen P., Besemer, Britta, Munder, Markus, Brossart, Peter, Fuhrmann, Stephan, Lindemann, Hans-Walter, Weisel, Katja, Duerig, Jan, Goldschmidt, Hartmut

Get full text

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma by Emde-Rajaratnam, Martina, Beck, Susanne, Benes, Vladimir, Salwender, Hans, Bertsch, Uta, Scheid, Christoph, Hänel, Mathias, Weisel, Katja, Hielscher, Thomas, Raab, Marc S, Goldschmidt, Hartmut, Jauch, Anna, Maes, Ken, De Bruyne, Elke, Menu, Eline, De Veirman, Kim, Moreaux, Jérôme, Vanderkerken, Karin, Seckinger, Anja, Hose, Dirk

“…Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing…”
Get full text

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries by Seckinger, Anja, Salwender, Hans, Martin, Hans, Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Hummel, Manuela, Jauch, Anna, Knauf, Wolfgang, Emde-Rajaratnam, Martina, Beck, Susanne, Neben, Kai, Dührig, Jan, Lindemann, Walter, Schmidt-Wolf, Ingo G H, Hänel, Mathias, Blau, Igor W, Weisel, Katja, Weinhold, Niels, Raab, Marc S, Goldschmidt, Hartmut, Choon-Quinones, Mimi, Hose, Dirk

“…Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; =…”
Get full text

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age by Mai, Elias K., Miah, Kaya, Bertsch, Uta, Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Benner, Axel, Salwender, Hans J., Goldschmidt, Hartmut

Get full text

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma by Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W, Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof, Goldschmidt, Hartmut

“…Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e…”
Get full text

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial by Scheid, Christof, Sonneveld, Pieter, Schmidt-Wolf, Ingo G H, van der Holt, Bronno, el Jarari, Laila, Bertsch, Uta, Salwender, Hans, Zweegman, Sonja, Blau, Igor Wolfgang, Vellenga, Edo, Weisel, Katja, Pfreundschuh, Michael, Jie, Kon-Siong, Neben, Kai, van de Velde, Helgi, Duehrsen, Ulrich, Schaafsma, M Ron, Lindemann, Walter, Kersten, Marie José, Peter, Norma, Hänel, Mathias, Croockewit, Sandra, Martin, Hans, Wittebol, Shulamiet, Bos, Gerard Mj, van Marwijk-Kooy, Marinus, Wijermans, Pierre, Goldschmidt, Hartmut, Lokhorst, Henk M

“…Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of…”
Get full text

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation by NEBEN, Kai, JAUCH, Anna, HO, Anthony D, HOSE, Dirk, GOLDSCHMIDT, Hartmut, BERTSCH, Uta, HEISS, Christiane, HIELSCHER, Thomas, SECKINGER, Anja, MORS, Tina, MÜLLER, Nadine Zoe, HILLENGASS, Jens, RAAB, Marc S

“…Chromosomal abnormalities have been shown to play a major role in disease evolution of multiple myeloma. Specific changes in interphase cells can be detected…”
Get full text

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma by Mai, Elias K., Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M., Scheid, Christof, Weisel, Katja C., Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor W., Hänel, Mathias, Salwender, Hans J., Benner, Axel, Raab, Marc S., Goldschmidt, Hartmut, Weinhold, Niels

“…Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed…”
Get full text

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor by Sprynski, Anne Catherine, Hose, Dirk, Caillot, Laurent, Réme, Thierry, Shaughnessy, John D., Barlogie, Bart, Seckinger, Anja, Moreaux, Jérôme, Hundemer, Michael, Jourdan, Michel, Meißner, Tobias, Jauch, Anna, Mahtouk, Karène, Kassambara, Alboukadel, Bertsch, Uta, Rossi, Jean François, Goldschmidt, Hartmut, Klein, Bernard

“…A plethora of myeloma growth factors (MGFs) has been identified, but their relative importance and cooperation have not been determined. We investigated 5 MGFs…”
Get full text

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma by HOSE, Dirk, REME, Thierry, HILLENGASS, Jens, BERTSCH, Uta, NEBEN, Kai, MÖHLER, Thomas, ROSSI, Jean Francois, JAUCH, Anna, KLEIN, Bernard, GOLDSCHMIDT, Hartmut, HIELSCHER, Thomas, MOREAUX, Jérôme, MESSNER, Tobias, SECKINGER, Anja, BENNER, Axel, SHAUGHNESSY, John D, BARLOGIE, Bart, YIMING ZHOU

“…Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin…”
Get full text

Induction of angiogenesis by normal and malignant plasma cells by Hose, Dirk, Moreaux, Jérôme, Meissner, Tobias, Seckinger, Anja, Goldschmidt, Hartmut, Benner, Axel, Mahtouk, Karène, Hillengass, Jens, Rème, Thierry, De Vos, John, Hundemer, Michael, Condomines, Maud, Bertsch, Uta, Rossi, Jean-François, Jauch, Anna, Klein, Bernard, Möhler, Thomas

“…Abundant bone marrow angiogenesis is present in almost all myeloma patients requiring therapy and correlated to treatment response and survival. We assessed…”
Get full text